E 52862

Drug Profile

E 52862

Alternative Names: E-52862; E-52862.HCl; MR-309; S1A; S1RA

Latest Information Update: 20 Dec 2016

Price : $50

At a glance

  • Originator Esteve
  • Developer ESTEVE
  • Class Non-opioid analgesics
  • Mechanism of Action Sigma-1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diabetic neuropathies; Neuropathic pain; Postherpetic neuralgia; Postoperative pain
  • Preclinical Osteoarthritis

Most Recent Events

  • 28 Nov 2016 Efficacy and adverse event data from a phase II trial in Post-operative pain presented at the 16th World Congress on Pain (WCP-2016)
  • 28 Nov 2016 Esteve completes enrolment in the phase II trial for Post-Operative Pain in Spain
  • 26 Sep 2016 Efficacy and adverse events data from a phase II trial in Post-surgical neuropathic pain presented at the 16th World Congress on Pain (WCP-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top